Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
115 participants
INTERVENTIONAL
2025-05-05
2025-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants between the ages of 39-64 with various skin types were enrolled for participation. Participants visited the clinic three times for collection of outcome metrics at baseline, 8 weeks, and 12 weeks. Participants also came to the lab at 4 weeks for a compliance check. Measurements included: expert clinical grading, digital imaging, subjective assessment of skin, and clinical grade-images.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles
NCT03312543
Clinical Trial to Evaluate Safety and Efficacy of a Facial and Lip Moisturizer in Adult Subjects Undergoing a Facial Dermatologic Procedure With Fractional CO2 Laser
NCT05272787
Safety and Effectiveness Evaluation of the Device in Achieving Submental Lift
NCT02832674
The Effects of an LED Face Mask & Neck and Chest Mask On Skin Health
NCT07025837
The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars
NCT02103816
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Daily LED and Vibration Use
Participants will use the device once daily for 12-15 minutes for 12-weeks. The device delivers LED (red light, red+infrared, and blue light) and vibration to the eye and scalp area.
LED Light Treatment
The device will guide participants through a treatment that cycles through Red (4 minutes), Red + Infrared (4 minutes), and Blue (4 minutes) LED therapy in combination with vibration therapy, for a 12-minute treatment. Participants will be asked to use the device Monday through Saturday, on a clean face, as part of their evening routine.
Vibration Only
On each Sunday of the 12-week program, participants will be asked to complete a 15-minute vibration-only treatment session as part of their evening routine.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LED Light Treatment
The device will guide participants through a treatment that cycles through Red (4 minutes), Red + Infrared (4 minutes), and Blue (4 minutes) LED therapy in combination with vibration therapy, for a 12-minute treatment. Participants will be asked to use the device Monday through Saturday, on a clean face, as part of their evening routine.
Vibration Only
On each Sunday of the 12-week program, participants will be asked to complete a 15-minute vibration-only treatment session as part of their evening routine.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is between the ages of 35-65
* Male subjects agree to remove all facial hair 24-48 hours prior to each visit and remain clean shaven daily throughout the study
* Subject is of any Fitzpatrick (at least one of each, to be recorded)
* Subject is of any of the following (Caucasian, African American, Asian, Hispanic) (at least one of each, to be recorded)
* Subject has Self-Perceived Sensitive skin or Self-Perceived Non-Sensitive skin (approximately 50% sensitive and 50% non-sensitive)
* Subject has the following on face (mild or greater):
Fine lines, ≥3 on 10-point scale Wrinkles, ≥3 on 10-point scale Dull skin, ≥3 on 10-point scale Sagging, ≥3 on 10-point scale Uneven skin tone Roughness/texture At least one dark spot
* Subject agrees to return all used and unused test materials at the end of the study
* Subjects will use their regular SPF product or will use an SPF product provided by the Sponsor (if they do not have an SPF product) and practice sun safe practices for the duration of the study (Hat, sunglasses, etc.)
* Subject agrees not to introduce any new cosmetic or toiletry products during the study other than the products provided in this study
* Subject is willing to use a cosmetic device on their face
* Subject is dependable and able to follow directions as outlined in the protocol and anticipates being available for all study visits
* Subject is willing to participate in all study evaluations
* Subject is in generally good health and has a current Panelist Profile Form on file at ECRL
* Subject agrees to sign a Photography Release Form, providing consent for the capture of digital images for use in relation to this clinical study
* Subject has completed a HIPAA Authorization Form in conformance with 45 CFR Parts 160 and 164
* Subject understands and has signed an Informed Consent Form in conformance with 21 CFR Part 50: "Protection of Human Subjects."
Exclusion Criteria
* Subject has been part of a clinical test for a LED device, microcurrent device or other facial device within the last 6 months
* Subject has eye sensitivity to light that may interfere with the use/application of the test product
* Subject has received treatment with sympathomimetics, antihistamines, vasoconstrictors, non-steroidal anti-inflammatory agents, and/or systemic or topical corticosteroids within one week prior to initiation of the study
* Subject has a history of acute or chronic dermatologic, medical, and/or physical conditions which would, in the opinion of the Principal Investigator, preclude application of the test material and/or could influence the outcome of the study
* Subject has a history of atopic eczema, psoriasis, or onychomycosis
* Subject chronically uses substances such as alcohol, tobacco, recreational drugs, etc.
* Subject is currently taking certain medications which, in the opinion of the Principal Investigator, may interfere with the study
* Subject exhibits any facial tattoos/tattooed cosmetics, eyelash extensions, rashes, scratches, scars, or burn marks on the test site (face) which may interfere with the study
* Subject has known allergies to skin treatment products or cosmetics, toiletries, and/or topical drugs
* Subject is unable to communicate or cooperate with the Principal Investigator, language problems, etc.
* Subject is on another study utilizing the same test sites (Face)
* Subject is an employee of testing firms/laboratories, cosmetic or raw goods manufacturers or suppliers
* Subject has any planned medical or cosmetic procedures planned during the course of the study that, at the discretion of the Principal Investigator, may interfere with the study
* Subject has a history of skin cancer, or is currently undergoing treatment for active cancer of any kind
* Subject has diabetes.
35 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eurofins CRL Cosmetics, Inc.
UNKNOWN
Therabody, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eurofins CRL Cosmetics, Inc
Piscataway, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ECRLNJ2025-0269 BI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.